Molecular Detection Inc. (MDI), a developer of Detect-Ready tests for infectious disease diagnosis, has been awarded a $244,500 federal Therapeutic Discovery Project grant, to support the US clinical development program for MDI's Detect-Ready panel.
MDI’s Detect-Ready panel detects carriers of MRSA (methicillin-resistant S aureus) and related pathogens as part of hospital-based screening programs aimed at decreasing the high incidence and costs of MRSA infections.
MDI’s Detect-Ready panel is a qualitative real-time PCR in-vitro diagnostic test that is marketed in the European Union and Australia.
The panel’s CE-mark label in the EU was recently expanded to include the detection of colonization with MSSA (methicillin-sensitive S aureus) and other bacteria, in addition to MRSA
MDI said that the Detect-Ready panel, compatible with a number of the real time-PCR platforms, shows accuracy, speed, flexibility and cost-effectiveness for healthcare providers.
MDI CEO and chairman Todd Wallach said that the potential of Detect-Ready MRSA panel is to reduce healthcare costs while improving quality of care make it fitting that the US Department of Health and Human Services selected our application for funding under this new program.